St. Jude Medical (STJ) CEO Spills the Beans on PFO Closure Trial

7/24/2012 8:31:09 AM

Dan Starks, the CEO of St Jude Medical, stated during a quarterly earnings call last week that results of the RESPECT trial of PFO closure for crytpogenic stroke were “favorable” and that the full trial results will be presented in October at the TCT meeting in Miami. But his statement raises more questions than it answers. It should be noted that it is impossible to ascertain the actual results of the trial from his remarks. He did not even state whether the trial had met its primary endpoint, and there are always potential dangers when the full data from a large trial are analyzed. Further, when asked to confirm whether RESPECT was indeed scheduled for presentation at TCT, TCT’s Gregg Stone told CardioBrief that “the submission deadline [for late-breaking clinical trials] has not even been reached yet.”

Read at Forbes

Read Article at

Related Companies

News Categories

• Forbes

• St. Jude Medical, Inc.

• Medical Devices

• Medical Dev. & Diag. - Industry